Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Danaher has demonstrated strong growth potential, as evidenced by its increase in performance obligations from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, indicating robust demand for its scientific instruments and consumables. The company is anticipating a ramp-up in the Life Sciences segment, projected at approximately 4.5% in 4Q25, driven by favorable comparisons in Genomics, recovery in China, and new product launches. Additionally, with the Cepheid Respiratory segment appearing de-risked and expected revenues of $300-350 million in 3Q25 and $450-500 million in 4Q25, the outlook for Danaher’s operational performance remains optimistic amidst strategic adjustments.

Bears say

Danaher's outlook presents concerns primarily due to a decline in expected revenue recognition from 2Q25 obligations, which fell from 48% to 46%. Additionally, the company faces significant risks from potential geopolitical disruptions, unfavorable foreign exchange conditions, and uncertainties regarding the recovery of high-growth markets, particularly in China. Despite slightly below-expected guidance for Biotechnology and Life Sciences revenue in 3Q25, these fundamental challenges cast doubt on the company's overall financial resilience.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $250.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $250.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.